Cytori Therapeutics (CYTX)

Business description

Cytori is focused on the development of cellular therapeutics for the treatment of impaired hand function in scleroderma, osteoarthritis of the knee, and radiation exposure-associated deep thermal burns.

Share price chart

Share chart

Stock data

Market cap.US$93m
Last closeUS$0.67
High / Low (52 weeks)US$2.5 / US$0.4
Stock market listingUS
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(32.2)(40.9)(72)
Relative *(31.7)(40.7)(74.8)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Athersys
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLight Life Sciences Inv
BioLineRx Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio BTG
Can-Fite BioPharma Capstone Therapeutics
Carmat Celldex Therapeutics
Cellectis Celyad
Cerulean Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
Consort Medical Curis
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech Molecular Partners
MolMed Mologen AG
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics NeoStem
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Tonix Pharmaceuticals
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB UDG Healthcare
uniQure NV Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology

Company news

Correcting The Facts On Cytori Therapeutics (CYTX)

Tue, 14 Apr 2015 17:20:34 GMT

Cytori Therapeutics Inc Capital Ventures International Bought New Stake

Thu, 14 May 2015 12:22:33 GMT

Oversold Stocks: Dillard's, Inc. (NYSE:DDS), Cytori Therapeutics Inc (NASDAQ ...

Mon, 18 May 2015 12:45:00 GMT

Stock Runners: Cytori Therapeutics, Inc. (NASDAQ:CYTX), Alnylam ...

Fri, 22 May 2015 14:15:00 GMT

Cytori Therapeutics Inc (CYTX) Jumps 7.84% on April 30

Thu, 30 Apr 2015 21:04:28 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2013A 12.2 (32.6) (38.1) (56.2) N/A N/A
2014A 10.1 (34.7) (41.2) (52.5) N/A N/A
2015E N/A N/A N/A N/A N/A N/A
2016E N/A N/A N/A N/A N/A N/A

Last updated on 24/04/2015

Investment summary

Cytori has FDA approval for the pivotal Phase III STAR Trial, enrolling 80 patients with impaired hand function from scleroderma at up to 20 US sites. Enrolment should start in the next few months. This uses ECCS-50: a specific ADRC preparation. This has orphan status in the EU. A 12-month update on the small Scleradec-I trial has been disclosed. Cytori's exclusive Asian licensee, Lorem Vascular, has been granted regulatory clearance for Celution by the CFDA. This triggers a major stock purchase by Lorem for China. FY14 revenues were $7.6m with a loss of $38.5m. End 2014 cash was $14.6m with debt of $25.4m. Edison's forecasts are under review.

Last updated on 06/05/2015

Industry outlook

The $14.1m BARDA thermal burns therapy contract is progressing. A 90-patient US Phase II study in knee osteoarthritis is underway; data are due in H216. Cruciate ligament and knee meniscus indications may be developed. A Japanese urinary incontinence study is part-sponsored. A GMP Celase enzyme used to prepare cells will be available from May.

Last updated on 06/05/2015

Key management

Marc Hendrick, CEO
Tiago Girao, CFO

Company address

3020 Callan Road
San Diago
CA 92121
United States
+1.858.458.0900
View website